Hosseini M Rajaei Z, Alaei H. Effects of crocin on rotational behavior, lipid peroxidation and nitrite levels
in rat’s brain striatum in an experimental model of parkinson’s disease. Journal of Isfahan Medical School.
2015; 33(336): 780-91.
2. Salgado S, Williams N, Kotian R, Salgado M. An evidence-based exercise regimen for patients with mild
to moderate parkinson’s disease. Brain Sci. 2013; 3(1): 87-100.
3. Liu B, Dluzen DE. Oestrogen and nigrostriatal dopaminergic neurodegeneration: animal models and
clinical reports of Parkinson's disease. Clinical and experimental pharmacology and physiology.
2007;34(7):555-65.
4. Cho H-S, Shin M-S, Song W, Jun T-W, Lim B-V, Kim Y-P, et al. Treadmill exercise alleviates short-term
memory impairment in 6-hydroxydopamine-induced Parkinson’s rats. J Exerc Rehabil. 2013; 9(3): 354-
61.
5. Goes A, Souza L, Del Fabbro L, De Gomes M, Boeira S, Jesse C. Neuroprotective effects of swimming
training in a mouse model of Parkinson’s disease induced by 6-hydroxydopamine. Neuroscience. 2014;
256: 61-71.
6. Archer T, Fredriksson A. Delayed exercise-induced functional and neurochemical partial restoration
following MPTP. Neurotox Res. 2012; 21(2): 210-21.
7. Archer T, Garcia D, Fredriksson A. Restoration of MPTP-induced deficits by exercise and Milmed®
cotreatment. PeerJ. 2014; 2:e531. doi: 10.7717/peerj.531
8. Liu B, Dluzen DE. Oestrogen and nigrostriatal dopaminergic neurodegeneration: animal models and
clinical reports of Parkinson's disease. Clinical and experimental pharmacology and physiology.
2007;34(7):555-65.
9. Cookson MR. The biochemistry of Parkinson’s disease. Annu Rev Biochem 2005;74:29-52.
10. Lohmann E, Periquet M, Bonifati V, et al. How much phenotypic variation can be attributed to parkin
genotype? Ann Neurol 2003;54(2):176-85.
11. Brücke T, Wöber C, Podreka I, Wöber-Bingöl C, Asenbaum S, Aull S, et al. D2 receptor blockade by
flunarizine and cinnarizine explains extrapyramidal side effects. A SPECT study. Journal of Cerebral
Blood Flow & Metabolism. 1995;15(3):513-8.
12. Berry C, La Vecchia C, Nicotera P. Paraquat and Parkinson’s disease. Cell Death Differ. 2010; 17(7):
1115-25.
13. Pramstaller PP, Schlossmacher MG, Jacques TS, et al. Lewy body Parkinson’s disease in a large pedigree
with 77 Parkin mutation carrier. Ann Neurol 2005;58(3):411-22.
14. zeigler, H. D. sand Alheid, G. F. basal ganglia in: paxions, G, the rat nervous system, 2 nd edition,
academic press, 1996. P. 579-614.
15. ebadi, M. Srinivasan, S.K and Baxi, M.D. oxidative stress and antioxidant therapy in parkinsons disease,
prog.neurobiol,1996. 48: p. 1-19.
16. Conway KA, Rochet J-C, Bieganski RM, Lansbury PT. Kinetic stabilization of the α-synuclein protofibril
by a dopamine-α-synuclein adduct. Science. 2001;294(5545):1346-9.
17. Jordi Clarimón* and Jaime Kulisevsky.Parkinson's Disease: From Genetics to Clinical Practice.Current
Genomics, 2013. 14: p. 560-567.
18. Savica R, Rocca WA, Ahlskog JE. When does Parkinson disease start? Archives of Neurology. 2010;
67(7): 798-801.
19. Boeve BF, Silber MH, Ferman TJ, Lucas JA, Parisi JE. Association of REM sleep behavior disorder and
neurodegenerative disease may reflect an underlying synucleinopathy. Mov Disord. 2001; 16(4): 622-30.
20. Chen T-F, Chiu M-J, Huang C-T, Tang M-C, Wang S-J, Wang C-C, et al. Changes in dietary folate intake
differentially affect oxidised lipid and mitochondrial DNA damage in various brain regions of rats in the
absence/presence of intracerebroventricularly injected amyloid β-peptide challenge. British journal of
nutrition. 2011;105(09):1294-302.
21. Berry C, La Vecchia C, Nicotera P. Paraquat and Parkinson’s disease. Cell Death Differ. 2010; 17(7):
1115-25.
22. Goedert M. Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci. 2001; 2(7): 492-501. 14.
Lotharius J, Brundin P. Pathogenesis of Parkinson’s disease: dopamine, vesicles and α-synuclein. Nat Rev
Neurosci. 2002; 3(12): 932-42.
23. Hampe C, Ardila-Osorio H, Fournier M, Brice A, Corti O. Biochemical analysis of Parkinson’s
diseasecausing variants of Parkin, an E3 ubiquitin–protein ligase with monoubiquitylation capacity.
Biochim Biophys Acta.. 2006; 15(13): 2059-75.
24. . Ragland M, Hutter C, Zabetian C, Edwards K. Association between the ubiquitin carboxyl-terminal
esterase L1 gene (UCHL1) S18Y variant and Parkinson’s disease: a HuGE review and meta-analysis. Am
J Epidemiol. 2009; 170(11): 1344-57.
25. Gandhi S, Muqit M, Stanyer L, Healy D, AbouSleiman P, Hargreaves I, et al. Pink1 protein in normal
human brain and Parkinson’s disease. Brain. 2006; 129(7): 1720-3.
26. Lockhart P, Lincoln S, Hulihan M, Kachergus J, Wilkes K, Bisceglio G, et al. DJ-1 mutations are a rare
cause of recessively inherited early onset parkinsonism mediated by loss of protein function. J Med Genet.
2004; 41(3): e22. doi:10.1136/jmg.2003.011106.
27. Biskup S, West AB. Zeroing in on lrrk2-linked pathogenic mechanisms in Parkinson’s disease. Biochim
Biophys Acta. 2009; 1792(7): 625-33.
28. Ferreira M, Massano J. An updated review of Parkinson’s disease genetics and clinicopathological
correlations. Acta Neurol Scand. 2016;1-12. doi: 10.1111/ane.12616.
29. Thomas B, Beal MF. Molecular insights into Parkinson’s disease. F1000 Med Rep. 2011; 3:7.
doi:10.3410/M3-7.
30. Silvio Conedera a, Hulya Apaydin. FBXO7 mutations in Parkinson’s disease and multiple system atrophy.
Neurobiology of Aging xxx (2016) 1e5.138. O. von Bohlen und
31. Ramirez A, Heimbach A, Grundemann J, Stiller B, Hampshire D, Cid LP, Goebel I, Mubaidin AF, Wriekat
AL, Roeper J, et al. 2006. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2,
encoding a lysosomal type 5 P-type ATPase. Nat Genet 38: 1184–1191
32. Karkheiran, S., Shahidi, G.A., Walker, R.H., Paisan-Ruiz, C., 2015. PLA2G6-associated
dystoniaparkinsonism: case report and literature review. Tremor Other Hyperkinetic Mov. (N. Y.) 5, 317.
33. Delgado-Camprubi, M., Esteras, N., Soutar, M.P., Plun-Favreau, H., Abramov, A.Y., 2017. Deficiency of
Parkinson's disease-related gene Fbxo7 is associated with impaired mitochondrial metabolism by PARP
activation. Cell Death Differ. 24, 120–131.
34. Hruska KS, LaMarca ME, Scott CR, Sidransky E 2008. Gaucher disease: Mutation and polymorphism
spectrum in the glucocerebrosidase gene (GBA). Hum Mutat 29: 567–583
35. Ellen Sidransky and Grisel Lopez. The link between the GBA gene and parkinsonism. Lancet Neurol.
2012 Nov; 11(11): 986–998.
36. Thaler, A., Gurevich, T., Bar, S.A., Gana, W.M., Ash, E., Shiner, T., Orr-Urtreger, A., Giladi, N.,
Mirelman, A., 2017. A dose effect of mutations in the GBA gene on Parkinson's disease phenotype.
Parkinsonism Relat. Disord. 36, 47–51.
